Published in

American Association for Cancer Research, Cancer Research, 7(69), p. 2887-2895, 2009

DOI: 10.1158/0008-5472.can-08-3343

Links

Tools

Export citation

Search in Google Scholar

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells

Journal article published in 2009 by Marta Santisteban, Jennifer M. (Jennifer M.) Reiman ORCID, Michael K. (Michael K.) Asiedu, Marshall D. (Marshall D.) Behrens, Aziza Nassar ORCID, Kimberly R. (Kimberly R.) Kalli, Paul Haluska, James N. (James N.) Ingle, Lynn C. (Lynn C.) Hartmann, Masoud H. (Masoud H.) Manjili, Derek C. (Derek C.) Radisky, Soldano Ferrone, Keith L. (Keith L.) Knutson
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract The breast cancer stem cell (BCSC) hypotheses suggest that breast cancer is derived from a single tumor-initiating cell with stem-like properties, but the source of these cells is unclear. We previously observed that induction of an immune response against an epithelial breast cancer led in vivo to the T-cell–dependent outgrowth of a tumor, the cells of which had undergone epithelial to mesenchymal transition (EMT). The resulting mesenchymal tumor cells had a CD24−/loCD44+ phenotype, consistent with BCSCs. In the present study, we found that EMT was induced by CD8 T cells and the resulting tumors had characteristics of BCSCs, including potent tumorigenicity, ability to reestablish an epithelial tumor, and enhanced resistance to drugs and radiation. In contrast to the hierarchal cancer stem cell hypothesis, which suggests that breast cancer arises from the transformation of a resident tissue stem cell, our results show that EMT can produce the BCSC phenotype. These findings have several important implications related to disease progression and relapse. [Cancer Res 2009;69(7):2887–95]